Cargando…

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS(G12D) inhibitor MRTX1133

Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the activity of KRAS(G12D) mutant proteins, one of the main drivers in pancreatic cancer. To better unde...

Descripción completa

Detalles Bibliográficos
Autor principal: Orsburn, Benjamin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055375/
https://www.ncbi.nlm.nih.gov/pubmed/36993160
http://dx.doi.org/10.1101/2023.03.23.533981